Disease Overview：Constrictive Pericarditis（CP）
Constrictive pericarditis is a chronic cardiovascular condition characterized by progressive fibrosis, calcification, and thickening of the pericardium—leading to impaired diastolic filling of the heart. This restrictive physiology results in elevated systemic venous pressure, reduced cardiac output, and symptoms including fatigue, dyspnea on exertion, peripheral edema, ascites, and hepatic congestion. Diagnosis relies on multimodal imaging: echocardiography (showing septal bounce, respiratory variation in mitral inflow), cardiac CT or MRI (demonstrating pericardial thickening ≥4 mm or calcification), and hemodynamic assessment via right heart catheterization revealing equalized diastolic pressures across all cardiac chambers. While medical management addresses symptoms, definitive treatment requires pericardiectomy—the surgical removal of the rigid pericardium. Timing is critical: early intervention improves outcomes, whereas advanced disease with myocardial atrophy or fibrosis may limit functional recovery.
China offers distinct advantages for international patients seeking pericardiectomy. Leading cardiovascular centers—such as Fu Wai Hospital (National Center for Cardiovascular Diseases) and Shanghai Zhongshan Hospital—combine decades of specialized expertise in complex pericardial surgery with state-of-the-art intraoperative imaging, robotic-assisted techniques, and high-volume experience (>200 annual pericardiectomies). Published 5-year survival rates exceed 85% in carefully selected patients, with low perioperative mortality (<5%) comparable to top Western institutions. Crucially, total treatment costs—including surgery, ICU stay, diagnostics, and follow-up—are typically 40–60% lower than in the US or EU, without compromising safety or evidence-based protocols. As a dedicated medical tourism agency, we facilitate seamless access: pre-travel clinical evaluation, direct coordination with certified cardiovascular surgeons, transparent all-inclusive pricing, visa support, multilingual care coordination, andensuring continuity, clarity, and confidence throughout the patient journey.
Constrictive Pericarditis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Constrictive Pericarditis (Cardiovascular Department)
Non-Surgical / Conservative Management
*Indicated for mild, stable cases with preserved hemodynamics and no evidence of progressive constriction on serial imaging.*
- •Diuretics (Furosemide): 3–6 months trial; monitoring for renal function and electrolytes.
- •ACE inhibitors/ARBs: Only if concurrent hypertension or LV dysfunction; not disease-modifying.
- •Comprehensive baseline workup: ECG, chest X-ray, transthoracic echocardiography (TTE), NT-proBNP, renal panel, liver function, CBC.
- •Serial surveillance: Repeat TTE + cardiac MRI every 3–6 months (if available).
Surgical / Interventional Options
*Pericardiectomy is the only definitive treatment for confirmed constrictive pericarditis.*
- •Eligibility: Confirmed diagnosis via echocardiography + cardiac MRI/CT; NYHA Class II–IV symptoms; absence of severe pulmonary hypertension (mPAP < 50 mmHg) or irreversible RV failure.
- •Preoperative workup: Cardiac catheterization (RHC + LHC), CT angiography, pulmonary function test, coagulation panel, infectious screening.
- •Pericardiectomy (median sternotomy): Full surgical resection of calcified/scarred pericardium.
- •Minimally invasive pericardiectomy (limited cases): Reserved for non-calcified, early-stage disease; requires high-volume center expertise.
Special / Complex Condition Management
- •Concomitant coronary artery disease: On-pump CABG + pericardiectomy.
- •Severe pulmonary hypertension (mPAP ≥50 mmHg): Requires preoperative PAH-targeted therapy (e.g., sildenafil) + staged surgery; extended ICU stay.
- •Renal failure (eGFR <30 mL/min): Requires perioperative CVVH and nephrology co-management.
Quick Selection Guide
- •<65 years, no comorbidities, moderate-severe symptoms: Immediate pericardiectomy — highest long-term survival (>85% at 5 years); optimal ROI despite upfront cost.
- •≥75 years or frailty (CFS ≥5): Conservative management + palliative diuresis, unless life-threatening tamponade physiology; avoid surgery if predicted 30-day mortality >15%.
- •Budget-constrained (<$5,000 USD): Prioritize diagnostic confirmation (TTE + MRI) to rule out mimics (e.g., restrictive cardiomyopathy); defer surgery until funding secured—delay beyond 6 months increases myocardial atrophy risk.
- •Comorbid diabetes + CKD: Require integrated nephrology/cardiology prehabilitation; budget $12,000–$15,000 to cover extended ICU and dialysis support.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Constrictive Pericarditis Medical Vacation Packages
Curated transparent all-inclusive packages combining Constrictive Pericarditis treatment with China top medical destinations:
